Early, aggressive therapy for rheumatoid arthritis: Concerns, descriptions, and estimate of outcome

Seminars in Arthritis and Rheumatism

Volumn 23, Issue 2, 1993, Pages 26-41

  Wilke, William S ^a   Sweeney, Thomas J ^a   Calabrese, Leonard H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

early treatment; Rheumatoid arthritis; treatment paradigms

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; AZATHIOPRINE; C REACTIVE PROTEIN; CD4 ANTIGEN; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; AUROTHIOGLUCOSE; COMPLEMENT; CYCLOSPORIN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TRIAMCINOLONE; ANTI INFLAMMATORY AGENTS, NON STEROIDAL;

ADULT; ALOPECIA; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPLICATION; DISABLED PERSON; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DYSPEPSIA; FEMALE; GRIP STRENGTH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RASH; RHEUMATOID ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; JOINT STIFFNESS; PAIN; PEPTIC ULCER; PLASMA VISCOSITY; SEDIMENTATION RATE; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; REVIEW; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; HYDROXYCHLOROQUINE; MALE; METHOTREXATE; MIDDLE AGE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027786836     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(10)80005-8     Document Type: Article

References (106)

1. Disease of the joints
2. Severe functional declines, work disability, and increased mortality in 75 rheumatoid arthritis patients studied over 9 years
3. Is mortality increased in rheumatoid arthritis?
4. Mortality and survival in rheumatoid arthritis: A 25-year prospective study in 100 patients
5. The development of disability in rheumatoid arthritis
6. Clinical and health status measures over time: Prognosis and outcome assessment in rheumatoid arthritis
7. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials
8. Does aggressive therapy of rheumatoid arthritis affect outcome?
9. Winning the battle, losing the war? Another editorial about rheumatoid arthritis
10. Remodeling the pyramid: A concept whose time has not yet come
11. Gold salts in the treatment of rheumatoid arthritis: A study of 245 cases
12. Effect of gold on progression of crosisions in rheumatoid arthritis: Better results with early treatment
13. Should disease-modifying agents be used in mild rheumatoid arthritis?
14. Early therapy with aurothioglucose and low-dose triamcinolone in rheumatoid arthritis: Results of a longitudinal study
15. The clinical and health status of patients with recent-onset rheumatoid arthritis
16. Statistical study of variation in systemic and articular indexes
17. A 7-day variability study of 499 patients with peripheral rheumatoid arthritis
18. Assessment of stiffness in rheumatology: The use of rating scales
19. Lack of objective evidence of stiffness in rheumatoid arthritis
20. Alpha EEG sleep and morning symptoms in rheumatoid arthritis
21. Sleep fragmentation in rheumatoid arthritis
22. Some observations on diurnal variation of grip
23. Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: Relation between discomfort and disability
24. Reliability and reproducibility of visual analog scale and numeric rating scale for therapeutic evaluation of pain in rheumatic patients
25. Measurement of pain
26. Accuracy of subjective measurements made with or without previous scores: An important source of error in serial measurement of subjective states
27. Measurement of pain
28. Problems associated with pain measurement in arthritis: Comparison of the visual analog scale and verbal rating scales
29. A simplified 28-joint quantitative articular index in rheumatoid arthritis
30. Reduced joint count indices in the evaluation of rheumatoid arthritis
31. Grading of tenderness as a source of inter-rater error in the Ritchie articular index
32. Comparison of four particular indices for use in clinical trials in rheumatoid arthritis: Patient, order and observer variation
33. Clinical, laboratory and radiographic features in early RA
34. Progression of radiological changes in rheumatoid arthritis
35. Does second-line therapy affect the radiologic progression of rheumatoid arthritis?
36. Rheumatoid arthritis: Treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression
37. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: The effects of duration on treatment response
38. Prospective study of early rheumatoid arthritis, I: Prognostic value of IgA rheumatoid factor
39. Rheumatoid factors specific for active rheumatoid arthritis
40. Relationship between the articular manifestations of rheumatoid arthritis and circulating immune complexes detected by three methods and specific classes of rheumatoid factors
41. Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis
42. Plasma viscosity-A new appraisal of its use as an index of disease activity in rheumatoid arthritis
43. Thrombocytosis in rheumatoid arthritis
44. Observations on the eosinophilia of certain patients with rheumatoid arthritis
45. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis
46. Which traditional measures should be used in rheumatoid arthritis clinical trials?
47. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
48. What should we hope to achieve when treating rheumatoid arthritis?
49. Can we develop simple response criteria for slow-acting antirheumatic drugs?
50. Preference for endpoint measures in clinical trials: Results of structured workshops
51. Clinical assessment of disease activity in rheumatoid arthritis: Evaluation of a functional test
52. The MACTAR patient preference disability questionnaire-An individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis
53. Methothrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires
54. Comparative measurement efficacy and sensitivity of five health status instruments for arthritis research
55. Influence of prognostic features on the final outcome in rheumatoid arthritis: A review of the literature
56. Course and prognosis in rheumatoid arthritis: A further report
57. The assessment of rheumatoid arthritis: A study based on measurements of the serum acute-phase reactants
58. Onset, early stages and prognosis of rheumatoid arthritis: A clinical study of 100 patients with 11-year follow-up
59. Prognostic value of early features in rheumatoid arthritis
60. Prognosis in rheumatoid arthritis: A longitudinal study of newly diagnosed younger adult patients
61. Factors related to the progression of joint destruction in rheumatoid arthritis
62. The natural history of rheumatoid arthritis: A 15-year follow-up study: The prognostic significance of features noted in the first year
63. Prognostic factors and diagnostic criteria in early rheumatoid arthritis
64. The development of disability in rheumatoid arthritis
65. Long-term outcome of treating rheumatoid arthritis: Results after 20 years
66. Prediction of erosiveness and rate of development of new erosisins in early rheumatoid arthritis
67. Factors predicting a poor life prognosis in rheumatoid arthritis: An 8-year prospective study
68. Health status as a predictor of mortality in rheumatoid arthritis: A 5-year study
69. Mortality predictors among 263 patients with rheumatoid arthritis
70. The assessment and prediction of functional disability in rheumatoid arthritis
71. Identification of HLA-Dwl4 genes in DR4 positive rheumatoid arthritis
72. HLA genes associated with rheumatoid arthritis: Identification of susceptibility alleles using specific oligonucleotide probes
73. Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment
74. Evidence of significant radiographic damage in rheumatoid arthritis within the first two years of disease
75. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxycholoroquine: A follow-up study
76. The stability of health status in rheumatoid arthritis: A five-year study of patients with established disease
77. Remodeling the pyramid-A concept whose time has come
78. Combination of auranofin and methotrexate as initial DMARD in RA
79. Reevaluating the therapeutic approach to rheumatoid arthritis: The “saw-tooth” strategy
80. Prognostic staging for therapy of rheumatoid arthritis
81. Rheumatoid arthritis: Pathophysiology and implications for therapy
82. Toxicity profile of disease-modifying antirheumatic drugs in rheumatoid arthritis
83. A toxicity index for comparison of side effects among different drugs
84. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
85. Rational use of disease-modifying antirheumatic drugs
86. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis
87. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
88. Functional disability in rheumatoid arthritis: Two different models in early and established disease
89. Current controversies in rheumatology: The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis
90. Combination therapy in RA
91. Long-acting drug combinations in RA: A formal overview
92. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study
93. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: A prospective, randomized, placebo-controlled study
94. Crysotherapy and concomitant use of antimalarial drug therapy in rheumatoid arthritis
95. Sulfasalazine alone or in combination with D-pcnicillamine in rheumatoid arthritis
96. Sulfasalazine in rheumatoid arthritis: Combination therapy with D-penicillamine or sodium aurothiomalate
97. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: Case observations
98. Treatment of rheumatoid arthritis (RA) with combination of D-penicillamine (DPC) and methotrexate (MTX)
99. The combined use of oral methotrexate and intramuscular gold in rheumatoid arthritis
100. Controlled trial of hydroxycholoroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis
101. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis-A comparative study
102. Synergistic and additive effects of disease-modifying antirheumatic drugs combined with chloroquine on the mitogen-drive stimulation of mononuclear cells
103. Combination therapy in rheumatoid arthritis-Study design
104. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulfasalazine or dapsone
105. Fifty years of antirheumatic therapy: The prognosis of rheumatoid arthritis
106. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update